Jane Street Group LLC Acquires Shares of 177,260 Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Jane Street Group LLC acquired a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 177,260 shares of the company's stock, valued at approximately $2,834,000. Jane Street Group LLC owned approximately 0.16% of Centessa Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. HighMark Wealth Management LLC acquired a new position in Centessa Pharmaceuticals in the 2nd quarter valued at about $840,000. TD Asset Management Inc grew its position in Centessa Pharmaceuticals by 40.5% in the second quarter. TD Asset Management Inc now owns 321,168 shares of the company's stock worth $2,900,000 after acquiring an additional 92,524 shares during the period. American Century Companies Inc. increased its stake in Centessa Pharmaceuticals by 1.3% during the second quarter. American Century Companies Inc. now owns 935,151 shares of the company's stock worth $8,444,000 after acquiring an additional 12,031 shares during the last quarter. XTX Topco Ltd purchased a new stake in Centessa Pharmaceuticals in the second quarter valued at $148,000. Finally, Farallon Capital Management LLC raised its position in Centessa Pharmaceuticals by 438.0% in the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company's stock valued at $18,024,000 after purchasing an additional 1,625,000 shares during the period. Hedge funds and other institutional investors own 82.01% of the company's stock.

Insider Buying and Selling

In related news, CEO Saurabh Saha sold 55,000 shares of the company's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $17.44, for a total value of $959,200.00. Following the completion of the transaction, the chief executive officer now directly owns 520,661 shares of the company's stock, valued at $9,080,327.84. This represents a 9.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Gregory M. Weinhoff sold 16,619 shares of the firm's stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $15.69, for a total transaction of $260,752.11. Following the sale, the insider now directly owns 206,750 shares in the company, valued at approximately $3,243,907.50. The trade was a 7.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 374,642 shares of company stock worth $6,425,926 over the last 90 days. 11.59% of the stock is owned by insiders.

Centessa Pharmaceuticals Stock Down 2.2 %

Shares of NASDAQ:CNTA traded down $0.39 during trading on Friday, hitting $17.16. The company's stock had a trading volume of 791,268 shares, compared to its average volume of 434,271. Centessa Pharmaceuticals plc has a fifty-two week low of $6.65 and a fifty-two week high of $18.97. The business has a 50 day moving average price of $16.64 and a two-hundred day moving average price of $13.61. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company has a market capitalization of $2.26 billion, a PE ratio of -11.22 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. As a group, research analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CNTA shares. Morgan Stanley raised Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. BMO Capital Markets boosted their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a research note on Monday, September 16th. Guggenheim increased their price objective on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a "buy" rating in a research report on Friday, November 15th. Jefferies Financial Group boosted their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, September 11th. Finally, B. Riley began coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a "buy" rating and a $33.00 price target for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $25.83.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.